Patents by Inventor Fritz Blatter

Fritz Blatter has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • SALTS OF DASATINIB IN CRYSTALLINE FORM
    Publication number: 20160168143
    Abstract: The present invention primarily relates to molecular crystalline substances, preferably salts of Dasatinib in crystalline form, comprising a compound of formula 1, preferably a cation of a compound of formula 1, and a second compound selected from the group consisting of glutaric acid, nicotinic acid and saccharin, preferably an anion thereof. The Invention is further related to pharmaceutical compositions comprising such a substance. Furthermore, the Invention relates to processes for preparing said substances. The invention also relates to several aspects of using said substances or pharmaceutical compositions to treat a disease.
    Type: Application
    Filed: July 22, 2014
    Publication date: June 16, 2016
    Inventors: Andreas HAFNER, Fritz BLATTER, Martin SZELAGIEWICZ, Bernd SIEBENHAAR, Tiziana CHIODO, Tobias HINTERMANN, Beate SALVADOR, Marcus VOSSEN
  • Multicomponent crystals comprising dasatinib and selected co-crystal formers
    Patent number: 9340536
    Abstract: Provided are a multicomponent crystalline system (co-crystal), use thereof, as well as a process for obtaining the same. The said multicomponent crystalline system (co-crystal) comprises Dasatinib and a second compound selected from methyM-hydrobenzoate, nicotinamide, ethyl gallate, methyl gallate, propyl gallate, ethyl maltol, vanillin, menthol, or (1R,2S,5R)-(?)-menthol.
    Type: Grant
    Filed: June 13, 2013
    Date of Patent: May 17, 2016
    Assignee: BASF SE
    Inventors: Tiziana Chiodo, Andreas Hafner, Tobias Hintermann, Beate Salvador, Martin Szelagiewicz, Fritz Blatter, Bernd Siebenhaar, Marcus Vossen
  • Crystalline asenapine hydrochloride salt forms
    Patent number: 9303036
    Abstract: Novel crystalline HCl salts of Asenapine, methods of their preparation and related pharmaceuticals and treatments are disclosed.
    Type: Grant
    Filed: May 15, 2012
    Date of Patent: April 5, 2016
    Assignee: Sandoz AG
    Inventors: Fritz Blatter, Katharina Reichenbächer
  • Multicomponent crystalline system comprising deferasirox and isonicotinamide and a process for the preparation thereof
    Patent number: 9290452
    Abstract: The present invention refers to a multicomponent crystalline system (co-crystal) comprising a compound of formula (1) (4-[3,5-Bis(2-hydroxyphenyl)-1H-1,2,4-triazol-1-yl]benzoic acid; INN: Deferasirox) formula (1) and a compound of formula (2) (Isonicotinamide; pyridine-4-carboxamide) formula (2), as well as to a process for obtaining the same.
    Type: Grant
    Filed: August 5, 2013
    Date of Patent: March 22, 2016
    Assignee: BASF SE
    Inventors: Andreas Hafner, Fritz Blatter, Eva Roedel, Martin Szelagiewicz, Tiziana Chiodo, Tobias Hintermann, Beate Salvador, Marcus Vossen
  • Multicomponent system of rosuvastatin calcium salt and sorbitol
    Patent number: 9249108
    Abstract: A novel solid form of Rosuvastatin comprises as the active ingredient a salt of bis[(E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)-amino]pyrimidin-5-yl]-(3R,5S)-3,5-dihydroxyhept-6-enoic acid] and sorbitol. The crystal comprising the two components, and minor amounts of water, shows improved properties such as crystallization behavior and stability.
    Type: Grant
    Filed: November 21, 2011
    Date of Patent: February 2, 2016
    Assignee: BASF SE
    Inventors: Andreas Hafner, Fritz Blatter, Martin Szelagiewicz, Bernd Siebenhaar
  • CRYSTALLINE FORMS OF PITAVASTATIN CALCIUM
    Publication number: 20160024010
    Abstract: The present invention is directed to new crystalline forms of Pitavastatin hemicalcium salt, referred to hereinafter as polymorphic Forms A, B, C, D, E and F, as well as the amorphous form. Furthermore, the present invention is directed to processes for the preparation of these crystalline forms and the amorphous form and pharmaceutical compositions comprising these crystalline forms or the amorphous forms.
    Type: Application
    Filed: October 1, 2015
    Publication date: January 28, 2016
    Applicant: NISSAN CHEMICAL INDUSTRIES, LTD.
    Inventors: Paul Adriaan VAN DER SCHAAF, Fritz BLATTER, Martin SZELAGIEWICZ, Kai-Uwe SCHOENING
  • Crystalline salts of Asenapine with organic di-acids and tri-acids
    Patent number: 9169262
    Abstract: Novel crystalline salts of Asenapine (I) with organic di-acids and tri-acids and to methods of their preparation are disclosed along with related pharmaceutical compositions and methods of treating psychotic diseases or disorders.
    Type: Grant
    Filed: May 15, 2012
    Date of Patent: October 27, 2015
    Assignee: SANDOZ AG
    Inventors: Fritz Blatter, Katharina Reichenbächer
  • MULTICOMPONENT CRYSTALLINE SYSTEM COMPRISING NILOTINIB AND SELECTED CO-CRYSTAL FORMERS
    Publication number: 20150246901
    Abstract: The present invention relates to crystalline materials comprising nilotinib and a carboxylic acid, carboxylic acid ester, carboxylic acid amide or sulfonic acid as a co-crystal former, and to pharmaceutical compositions comprising said materials. The invention also relates to processes for preparing said crystalline materials and to methods of using said crystalline materials to treat a disease condition in which tyrosine kinase inhibition is beneficial.
    Type: Application
    Filed: October 16, 2013
    Publication date: September 3, 2015
    Inventors: Tiziana Chiodo, Andreas Hafner, Tobias Hintermann, Beate Salvador, Martin Szelagiewicz, Fritz Blatter, Eva Roedel, Marcus Vossen
  • MULTICOMPONENT CRYSTALLINE SYSTEM COMPRISING DEFERASIROX AND ISONICOTINAMIDE AND A PROCESS FOR THE PREPARATION THEREOF
    Publication number: 20150175544
    Abstract: The present invention refers to a multicomponent crystalline system (co-crystal) comprising a compound of formula (1) (4-[3,5-Bis(2-hydroxyphenyl)-1H-1,2,4-triazol-1-yl]benzoic acid; INN: Deferasirox) formula (1) and a compound of formula (2) (Isonicotinamide; pyridine-4-carboxamide) formula (2), as well as to a process for obtaining the same.
    Type: Application
    Filed: August 5, 2013
    Publication date: June 25, 2015
    Applicant: BASF SE
    Inventors: Andreas Hafner, Fritz Blatter, Eva Roedel, Martin Szelagiewicz, Tiziana Chiodo, Tobias Hintermann, Beate Salvador, Marcus Vossen
  • MULTICOMPONENT CRYSTALS COMPRISING DASATINIB AND SELECTED CO-CRYSTAL FORMERS
    Publication number: 20150133463
    Abstract: Provided are a multicomponent crystalline system (co-crystal), use thereof, as well as a process for obtaining the same. The said multicomponent crystalline system (co-crystal) comprises Dasatinib and a second compound selected from methyM-hydrobenzoate, nicotinamide, ethyl gallate, methyl gallate, propyl gallate, ethyl maltol, vanillin, menthol, or (1R,2S,5R)-(?)-menthol.
    Type: Application
    Filed: June 13, 2013
    Publication date: May 14, 2015
    Applicant: BASF SE
    Inventors: Tiziana Chiodo, Andreas Hafner, Tobias Hintermann, Beate Salvador, Martin Szelagiewicz, Fritz Blatter, Bernd Siebenhaar, Marcus Vossen
  • MULTICOMPONENT CRYSTALLINE SYSTEM OF VORICONAZOLE WITH FUMARIC ACID
    Publication number: 20150087657
    Abstract: A novel solid form of Voriconazole comprises the active ingredient (2R,3S)-2-(2,4-difluorophenyl)-3-(5-fluoropyrimidin-4-yl)-1-(1H-1,2,4-triazol-1-yl)butan-2-ol and fumaric acid. The solid composition comprising the two components shows improved properties such as water solubility, crystallization behavior and stability.
    Type: Application
    Filed: December 3, 2012
    Publication date: March 26, 2015
    Applicant: BASF SE
    Inventors: Andreas Hafner, Tobias Hintermann, Fritz Blatter, Eva Roedel
  • Crystalline compound of 7-[(3R)-3-amino-1-oxo-4-(2, 4, 5-trifluorophenyl)butyl]-5, 6, 7, 8-tetrahydro-3-(tri fluoromethyl)-1, 2, 4 -triazolo[4,3-A]pyrazin
    Patent number: 8916559
    Abstract: A crystalline compound of 7-[(3R)-3-amino-1-oxo-4-(2,4,5-trifluorophenyl)butyl]-5,6,7,8-tetrahydro-3-(trifluoromethyl)-1,2,4-triazolo[4,3-a]pyrazine (INN: Sitagliptin) of formula 1 with fumaric acid or a hydrate thereof, where the molar ratio of the compound of formula 1 to fumaric acid is 1:0.6 to 1:1.3 is described.
    Type: Grant
    Filed: August 12, 2010
    Date of Patent: December 23, 2014
    Assignee: Sandoz AG
    Inventors: Fritz Blatter, Katharina Reichenbächer
  • CRYSTALLINE FORMS OF PITAVASTATIN CALCIUM
    Publication number: 20140364614
    Abstract: The present invention is directed to new crystalline forms of Pitavastatin hemicalcium salt, referred to hereinafter as polymorphic Forms A, B, C, D, E and F, as well as the amorphous form. Furthermore, the present invention is directed to processes for the preparation of these crystalline forms and the amorphous form and pharmaceutical compositions comprising these crystalline forms or the amorphous forms.
    Type: Application
    Filed: August 26, 2014
    Publication date: December 11, 2014
    Applicant: NISSAN CHEMICAL INDUSTRIES, LTD.
    Inventors: Paul Adriaan VAN DER SCHAAF, Fritz BLATTER, Martin SZELAGIEWICZ, Kai-Uwe SCHOENING
  • CRYSTALLINE DAPAGLIFLOZIN HYDRATE
    Publication number: 20140323417
    Abstract: A crystalline dapagliflozin hydrate and a process for obtaining the same is described.
    Type: Application
    Filed: November 28, 2012
    Publication date: October 30, 2014
    Inventors: Fritz Blatter, Katharina Reichenbaecher
  • Crystalline forms of pitavastatin calcium
    Patent number: 8853405
    Abstract: The present invention is directed to new crystalline forms of Pitavastatin hemicalcium salt, referred to hereinafter as polymorphic Forms A, B, C, D, E and F, as well as the amorphous form. Furthermore, the present invention is directed to processes for the preparation of these crystalline forms and the amorphous form and pharmaceutical compositions comprising these crystalline forms or the amorphous forms.
    Type: Grant
    Filed: September 3, 2013
    Date of Patent: October 7, 2014
    Assignee: Nissan Chemical Industries Ltd.
    Inventors: Paul Adriaan Van Der Schaaf, Fritz Blatter, Martin Szelagiewicz, Kai-Uwe Schoening
  • Multicomponent crystalline system of rosuvastatin calcium salt and vanillin
    Patent number: 8841316
    Abstract: A novel solid form of Rosuvastatin comprises as the active ingredient a salt of bis[(E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)-amino]pyrimidin-5-yl]-(3R,5S)-3,5-dihydroxyhept-6-enoic acid] and vanillin or vanillin derivatives. The crystal comprising the two components, and minor amounts of water, shows improved properties such as crystallization behavior stability and decreased hydroscopic behavior.
    Type: Grant
    Filed: January 31, 2014
    Date of Patent: September 23, 2014
    Assignee: BASF SE
    Inventors: Andreas Hafner, Fritz Blatter, Martin Szelagiewicz, Bernd Siebenhaar
  • MULTICOMPONENT CRYSTALLINE SYSTEM OF ROSUVASTATIN CALCIUM SALT AND VANILLIN
    Publication number: 20140194453
    Abstract: A novel solid form of Rosuvastatin comprises as the active ingredient a salt of bis[(E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)-amino]pyrimidin-5-yl]-(3R,5S)-3,5-dihydroxyhept-6-enoic acid] and vanillin or vanillin derivatives. The crystal comprising the two components, and minor amounts of water, shows improved properties such as crystallization behavior stability and decreased hydroscopic behavior.
    Type: Application
    Filed: January 31, 2014
    Publication date: July 10, 2014
    Applicant: BASF SE
    Inventors: Andreas HAFNER, Fritz BLATTER, Martin SZELAGIEWICZ, Bernd SIEBENHAAR
  • NOVEL CRYSTALLINE SALTS OF ASENAPINE
    Publication number: 20140163083
    Abstract: Crystalline Asenapine salts of tartaric acid or succinic acid, wherein the salts are e.g. selected from the group consisting of Asenapine D, L-tartrate hydrate form A, Asenapine D, L-tartrate hydrate form B, Asenapine D, L-tartrate anhydrous form, Asenapine succinate form X, Asenapine succinate form, and Asenapine succinate form II are described as well as related pharmaceutical compositions and related treatment of psychotic diseases or disorders.
    Type: Application
    Filed: May 15, 2012
    Publication date: June 12, 2014
    Applicant: SANDOZ AG
    Inventors: Fritz Blatter, Katharina Reichenbächer
  • MULTICOMPONENT CRYSTALLINE SYSTEM OF EZETIMIBE AND PROLINE
    Publication number: 20140155371
    Abstract: Provided is a crystalline composition comprising a mixture of a compound of formula 1 (Ezetimibe) and proline or proline derivatives, or a hydrate/solvate thereof, as well as a process for obtaining the same. And a process for the purification of Ezetimibe is also disclosed.
    Type: Application
    Filed: July 24, 2012
    Publication date: June 5, 2014
    Applicant: BASF SE
    Inventors: Andreas Hafner, Tobias Hintermann, Martin Szelagiewicz, Bernd Siebenhaar, Fritz Blatter
  • CRYSTALLINE SODIUM SALT OF AN HIV INTEGRASE INHIBITOR
    Publication number: 20140135353
    Abstract: A crystalline sodium salt of a compound of formula I (INN: Raltegravir) or a hydrate/solvate thereof is disclosed as well as a process for obtaining the same.
    Type: Application
    Filed: April 27, 2012
    Publication date: May 15, 2014
    Applicant: SANDOZ AG
    Inventors: Fritz Blatter, Katharina Reichenbächer, Robert Ziegert, Josef Wieser, Johannes Ludescher